Ron Bose
机构: Associate Professor of Oncology, Washington University School of Medicine
主页: ronboselab.org
每年引用次数
引用次数
引用: 10,420
H-指数: 27
I10-指数 : 31
出版物: 48
Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
John Monsey , Wei Shen , Paul Schlesinger , Ron Bose
Journal of Biological Chemistry 285 ( 10) 7035 -7044
54
2010
Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer
Matthew J. Ellis , Ding Li , Dong Shen , Jingqin Luo
Cancer Research 72
2012
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Xuewu Zhang , Kerry A. Pickin , Ron Bose , Natalia Jura
Nature 450 ( 7170) 741 -744
285
2007
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data.
Runjun D. Kumar , Li-Wei Chang , Matthew J. Ellis , Ron Bose
PLOS ONE 8 ( 6)
19
2013
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis , Li Ding , Dong Shen , Jingqin Luo
Nature 486 ( 7403) 353 -360
1,122
2012
Human Proteinpedia enables sharing of human protein data.
Suresh Mathivanan , Mukhtar Ahmed , Natalie G Ahn , Hainard Alexandre
Nature Biotechnology 26 ( 2) 164 -167
146
2008
Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003
Nikhil Wagle , Nancy U Lin , Andrea L Richardson , Ignaty Leshchiner
Cancer Research 75
4
2015
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.
Runjun D. Kumar , Adam C. Searleman , S. Joshua Swamidass , Obi L. Griffith
Bioinformatics 31 ( 22) 3561 -3568
33
2015
Incorporating Genomics into Breast Cancer Clinical Trials and Care
Adel Tabchy , Cynthia X. Ma , Ron Bose , Matthew J. Ellis
Clinical Cancer Research 19 ( 23) 6371 -6379
15
2013
A Neu View of Invasive Lobular Breast Cancer
Ron Bose
Clinical Cancer Research 19 ( 13) 3331 -3333
4
2013
Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Chen Qiu , Mary K. Tarrant , Sung Hee Choi , Aruna Sathyamurthy
Structure 16 ( 3) 460 -467
190
2008
The ErbB kinase domain: structural perspectives into kinase activation and inhibition.
Ron Bose , Xuewu Zhang
Experimental Cell Research 315 ( 4) 649 -658
63
2009
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose , Shyam M. Kavuri , Adam C. Searleman , Wei Shen
Cancer Discovery 3 ( 2) 224 -237
795
2013
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri , Naveen Jain , Francesco Galimi , Francesca Cottino
Cancer Discovery 5 ( 8) 832 -841
255
2015
Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
Ron Bose , Marcel Verheij , Adriana Haimovitz-Friedman , Kathleen Scotto
Cell 82 ( 3) 405 -414
761
1995
Ceramide generation by the reaper protein is not blocked by the caspase inhibitor, p35
Ron Bose , Po Chen , Andrea Loconti , Carsten Grüllich
Journal of Biological Chemistry 273 ( 44) 28852 -28859
46
1998
Protein tyrosine kinase-substrate interactions.
Ron Bose , Marc A Holbert , Kerry A Pickin , Philip A Cole
Current Opinion in Structural Biology 16 ( 6) 668 -675
49
2006
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li , Dong Shen , Jieya Shao , Robert Crowder
Cell Reports 4 ( 6) 1116 -1130
613
2013
Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer.
Ron Bose , Bob Fulton , Rick Wilson , Charles Perou
Cancer Research 73
2013
Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance.
Matthew J. Ellis , Shunqiang Li , Dong Shen , Li Ding
Cancer Research 73
2013